Late phase failure is a huge challenge for pharmaceutical companies running clinical trials. In fact, only 65% of phase III trials successfully lead to new drugs being approved (1). The primary reason behind this high failure rate is efficacy, with more than 60% of those phase III failures caused by poor response rates in large patient groups (2).
To address these low efficacy rates, more pharmaceutical companies have begun focusing their resources on solutions which ensure more confident go/no-go decision making. They recognize that the ability to select the right drug candidates for phase III trials and develop companion diagnostics for better patient stratification are the only way to gain this confidence and ultimately increase the efficacy of their drugs during clinical trials.Read More